上海医药
上海醫藥
상해의약
SHANGHAI MEDICAL & PHARMACEUTICAL JOURNAL
2013年
19期
27-31
,共5页
甘珏%徐珊萍%陈永法%胡廷熹
甘玨%徐珊萍%陳永法%鬍廷熹
감각%서산평%진영법%호정희
罕见病%罕用药%选定%激励
罕見病%罕用藥%選定%激勵
한견병%한용약%선정%격려
rare diseases%orphan drugs%designation%incentives
本文根据多个国家（地区）对罕见病和罕用药的界定和制定激励措施进行比较，通过分析罕见病和罕用药的现状来了解这些激励措施对罕用药选定的积极作用，探讨我国制定罕用药相关政策的思路。
本文根據多箇國傢（地區）對罕見病和罕用藥的界定和製定激勵措施進行比較，通過分析罕見病和罕用藥的現狀來瞭解這些激勵措施對罕用藥選定的積極作用，探討我國製定罕用藥相關政策的思路。
본문근거다개국가（지구）대한견병화한용약적계정화제정격려조시진행비교，통과분석한견병화한용약적현상래료해저사격려조시대한용약선정적적겁작용，탐토아국제정한용약상관정책적사로。
Based on the comparison of the deifnitions and the incentive measures for both rare diseases and orphan drugs in several countries and regions, their current situation was analyzed so as to learn the positive effects of these incentive measures on the designation of orphan drugs. Suggestions were proposed to explore the policies on the development of orphan drugs in China.
